This is a preview of subscription content, log in via an institution to check access.
References
Baxter EJ, Scott LM, Campbell PJ, East C, Fourclas N, Swanton S, et al., Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2 activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukaemia, but not in acute lymphoblastic leukaemia or chronic lymphocytic leukaemia. Blood 2005; 106: 3377–3379.
Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J . The V617F mutation in JAK2 is not found in childhood acute lymphoblastic leukemia. BrJ Haematol 2005; 130: 964–972.
Melzner I, Weniger MA, Menz CK, Moller P . Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 2006; 20: 157–158.
Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S et al. The V617F JAK2 mutation is uncommon in cancers and myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106: 2920–2921.
De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 2000; 109: 823–828.
Abroun S, Ishikawa H, Tsuyama N, Liu S, Otsuyama KM, Zheng X et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-1 in myeloma cells that highly express IL-6 receptor alpha. Blood 2004; 103: 2291–2298.
Bergsagel PL, Masellis S, Szczepek A, Mant MJ, Belch AR, Pilarski LM . In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56 and monotypic immunoglobulin light chain. Blood 1995; 85: 436–447.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fiorini, A., Farina, G., Reddiconto, G. et al. Screening of JAK2 V617F mutation in multiple myeloma. Leukemia 20, 1912–1913 (2006). https://doi.org/10.1038/sj.leu.2404332
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404332
- Springer Nature Limited
This article is cited by
-
High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation
Bone Marrow Transplantation (2014)
-
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Leukemia (2008)
-
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
Leukemia (2008)
-
The history of myeloproliferative disorders: before and after Dameshek
Leukemia (2008)
-
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
Leukemia (2008)